| |JULY 20268TOP STORIESBIGGEST-EVER MRNA VACCINE ANALYSIS BRINGS REASSURING FINDINGSDELHI'S DENGUE FIGHT GETS A MAJOR PUSH AS NADDA REVIEWS PLANSAUROBINDO PHARMA'S LANNETT ACQUISITION MARKS NEW US CHAPTERWHY GLENMARK SHARES FELL AFTER US FDA'S GOA PLANT INSPECTIONWHY DR REDDY'S WANTS INDIA TO THINK TWICE BEFORE CHANGING DRUG RULESA new mRNA Vaccine Analysis has delivered reassuring findings about the safety and effectiveness of mRNA vaccines. The review examined evidence from billions of vaccine doses administered worldwide. Researchers found that these vaccines continue to provide strong protection against severe infectious diseases. The mRNA Vaccine Analysis also confirmed that serious side effects remain rare.Experts said the technology has proven its value during the COVID-19 pandemic and could help fight future diseases. The review was published in The Lancet. It brought together findings from clinical trials, real-world studies, vaccine safety monitoring systems, and regulatory data. Researchers evaluated evidence collected over several years. They concluded that mRNA vaccines have a strong safety record while reducing the risk of severe illness, hospitalization, and death. PODelhi's dengue fight received a major boost after Union Health Minister Jagat Prakash Nadda chaired a high-level meeting to review the city's preparedness against dengue ahead of the peak transmission season. The review came as Delhi's dengue fight entered a crucial phase with authorities focusing on surveillance, hospital readiness, vector control, and public awareness.While the current dengue situation remains under control, the Centre has asked all agencies to stay fully prepared to prevent any spike in cases during the coming months. The meeting reviewed the evolving epidemiological situation, preparedness of hospitals, Glenmark shares came under pressure after the US FDA issued six observations following an inspection of the company's Goa plant. The development has put Glenmark shares in focus as investors assess whether the findings could affect the drugmaker's manufacturing operations and exports to the US market. While the company has received a Form 483 with six observations, it said it will respond to the regulator within the prescribed timeline and take the required corrective steps.India may need to rethink its India drug rules before making changes that could impact the country's position as a global leader in affordable medicines. Dr Reddy's Chairman Satish Reddy has warned that India should not accept regulatory data protection terms just to attract foreign investment. He said such a move could weaken the generic drug industry, which has helped India earn the title of the "pharmacy of the world" by supplying low-cost medicines to millions across the globe.Speaking about the ongoing policy debate, Reddy said protecting innovation is important, but it should not come at the cost of India's strong generic medicines business. According to him, any changes to India drug rules must strike a balance between encouraging research and preserving the country's competitive edge in generics. POmunicipal bodies, and the Delhi government. Officials also assessed disease surveillance systems, clinical management protocols, and ongoing vector control measures to ensure a coordinated response during the monsoon season. POAurobindo Pharma's Lannett Acquisition has officially entered a new phase with the successful completion of its USD 250 million buyout of US-based Lannett Company. The deal, which was first announced in July 2025, has now crossed the final regulatory hurdle after receiving FTC approval, marking a major milestone in Aurobindo's expansion in the US pharmaceutical market.The Acquisition strengthens the company's manufacturing footprint, broadens its generic drugs portfolio, and supports its long-term growth strategy in the United States. The acquisition was completed through the company's wholly owned subsidiary, Aurobindo Pharma USA Inc. (APUSA), on June 29, 2026. Following the completion of the transaction, Lannett Company, Inc. has been converted into Lannett Company LLC, which will continue to operate as a wholly owned subsidiary of APUSA. PO
< Page 7 | Page 9 >